Nuo Therapeutics, Inc. (AURX) Gross margin 2017–2025
Nuo Therapeutics, Inc. (AURX) gross margin by fiscal year — reported gross profit divided by reported revenue.
66.9%FY2025 · since FY2017: -51.3% → 66.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 66.9% | -10.9 pp |
| FY2024 | 77.8% | -1.5 pp |
| FY2023 | 79.3% | -3.6 pp |
| FY2022 | 82.9% | — |
| FY2019 | 21.6% | -66.5 pp |
| FY2018 | 88.1% | +139.4 pp |
| FY2017 | -51.3% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AURX financial trends
AURX RevenueAURX Net incomeAURX Net marginAURX Gross profitAURX Operating incomeAURX Operating marginAURX Operating cash flowAURX Free cash flowAURX Capital expendituresAURX Return on equityAURX Stock buybacksAURX Dividends paidAURX Total assetsAURX Total liabilitiesAURX Shareholders’ equityAURX overview →